Oslo, 26 March 2020 – Targovax ASA, today announces that Øystein Soug, CEO, will present the company and its development programs at the Solebury Trout Virtual Investor Conference. The presentation will be held at 12:00 p.m. EDT / 5:00 p.m. CET today.
To access the presentation please click here.
Following the presentation an archive of the event will be available on the Company’s website at www.targovax.com.
For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Media and IR enquires:
Andreas Tinglum – Corporate Communications (Norway)
Phone: +47 9300 1773
Activating the patient’s immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors. Targovax’s lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system to fight the cancer.
ONCOS-102 is currently being tested in mesothelioma, melanoma and peritoneal malignancies and has already shown promising clinical results both as monotherapy and in combination with chemotherapy, and a checkpoint inhibitor.